No one says stuff like this, putting themselves at

No one says stuff like this, putting themselves at risk for shareholders' lawsuits, unless they are mighty confident. From Mr. Ehrlich's recent letter to shareholders/PR:

The University has conducted pre-clinical research that they shared with us but asked that we not disclose the data as they “plan to publish it at a later day.”  A very brief summary of the data showed Kevetrin causing apoptosis (programmed cell death) in cancerous cells in addition to sensitizing and optimizing the cells to maximize the effectiveness of drugs used in combination with Kevetrin.  We will be releasing details about the University very shortly.

We have seen the data and it is very exciting to us, but, again, confidentiality agreements prevent us from providing any details at this time.

There is no comparison of Kevetrin to any other compound. I think that the interest that has been shown by organizations approaching us wishing to conduct and sponsor research speaks for itself as to what some of the brightest minds in oncology see in the data.

I believe that 2013 will be a bigger year for us with clinical data coming from multiple trials and that the best is still yet to come.